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Objectives This study was designed to analyze how patient preferences for survival versus quality-of-life change after hospi-
talization with advanced heart failure (HF).
Background Although patient-centered care is a priority, little is known about preferences to trade length of life for qual-
ity among hospitalized patients with advanced HF, and it is not known how those preferences change after
hospitalization.
Methods The time trade-off utility, symptom scores, and 6-min walk distance were measured in 287 patients in the
ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheter Effectiveness) trial at hos-
pitalization and again during 6 months after therapy to relieve congestion.
Results Willingness to trade was bimodal. At baseline, the median trade for better quality was 3 months’ survival time,
with a modest relation to symptom severity. Preference for survival time was stable for most patients, but in-
crease after discharge occurred in 98 of 145 (68%) patients initially willing to trade survival time, and was more
common with symptom improvement and after therapy guided by pulmonary artery catheters (p  0.034). Ad-
justing days alive after hospital discharge for patients’ survival preference reduced overall days by 24%, with the
largest reduction among patients dying early after discharge (p  0.0015).
Conclusions Preferences remain in favor of survival for many patients despite advanced HF symptoms, but increase further
after hospitalization. The bimodal distribution and the stability of patient preference limit utility as a trial end
point, but support its relevance in design of care for an individual patient. (J Am Coll Cardiol 2008;52:1702–8)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.028i
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udvances in the treatment of heart failure (HF) have
elayed disease progression and prolonged survival. Earlier
se of neurohormonal antagonists and devices has dimin-
shed untimely sudden death, leaving more patients with
ymptoms of advanced HF (1). As the symptomatic burden
s borne for a longer period of time, it becomes increasingly
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niversity Medical Center, Durham, North Carolina; §Division of Cardiology, Ohio
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lood Institute, National Institutes of Health, Bethesda, Maryland; ¶Division of
ardiology, University of Michigan Cardiovascular Center, Ann Arbor, Michigan;
Division of Cardiology, University of Calgary, Alberta, Canada; and the **Division
f Cardiology, Johns Hopkins, Baltimore, Maryland. This study was supported by
ontract N01-HV-98177 from the National Heart, Lung, and Blood Institute.s
Manuscript received March 28, 2008; revised manuscript received July 17, 2008,
ccepted August 4, 2008.mportant to understand the utility awarded by patients to
urvival, and how this may change. The Institute of Medicine
dvocates progress toward patient-centered care (2), in which
ndividual preferences are crucial and the patient is empowered
n therapeutic decision making. Yet, there is little understand-
ng about the trajectory of patient preferences in HF.
See page 1709
Many scales and questionnaires probe symptoms in HF, but
hese scores do not equate to the importance of survival to an
ndividual patient. The time trade-off (TTO) tool offers direct
ssessment of relative value placed by patients on survival time
ersus perceived symptomatic health (3). A study of the TTO
tility done by Jaagosild et al. (4) showed a high preference for
urvival among a heterogenous population of patients surviving
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ention. A previous study by Lewis et al. (5) showed a lower
reference for survival in severe HF, and Havranek et al. (6)
ave shown this measure to correlate with activity. It is not
nown how the preferences of hospitalized patients may
hange after discharge.
This study was planned within the ESCAPE (Evaluation
tudy of Congestive Heart Failure and Pulmonary Artery
atheter Effectiveness) study to understand how utilities
efined by hospitalized patients with advanced HF change
fter therapy designed to relieve congestive symptoms. The
ypothesis was that changes in patient preference would be
requent and linked to improvements in symptoms and
unctional capacity after hospitalization. In addition, the
tudy pre-specified exploration of a novel secondary end
oint of survival days adjusted by repeated TTO utilities.
ethods
he ESCAPE study was sponsored by the National Heart,
ung, and Blood Institute to compare therapy guided by
linical assessment alone with therapy guided by clinical
ssessment and pulmonary artery catheter (PAC) monitor-
ng on the primary end point of days alive out of the hospital
or 6 months. Criteria included current hospitalization with
t least 1 symptom and 1 sign of congestion, previous HF
ospitalization or usual daily dose of 160 mg furosemide,
eft ventricular ejection fraction 30%, and systolic blood
ressure 125 mm Hg. Patients were excluded for creati-
ine 3.5 mg/dl, milrinone use, or 3 g/kg/min dopa-
ine or dobutamine.
Informed consent was obtained before baseline assessment.
fter randomization, therapy was adjusted in both arms with
he goals of an estimated jugular venous pressure of8 cm and
esolution of orthopnea and edema, assessed qualitatively using
0 to 4 scale. Additional hemodynamic goals for patients
eceiving PAC were pulmonary capillary wedge pressure 15
m Hg and right atrial pressure 8 mm Hg.
The TTO instrument was administered verbally by the
tudy nurse at 1, 2, 3, and 6 months. Whenever possible, this
nstrument and written questions were administered in the
bsence of family. After a scripted introduction, the initial
uestion was “Would you prefer living 2 years in your current
tate of health or living 1 day in excellent health?” An answer
f 1 day, equated to a utility of 1/730 (0), would end the
cript. An answer of 2 years would be followed by the next
hoice, between living “2 years in your current state of health or
iving 1 year 11 months in excellent health.” After sequential
hoices, the number of months (24 months) in excellent
ealth that the respondent considered to be equivalent in value
o 24 months of survival in current health was recorded, and
his ratio was the utility (between 0 and 1). The number of
onths at the indifference point subtracted from 24 yielded the
umber of months of survival time that the patient would be
illing to trade. pThe TTO instrument, the
innesota Living with Heart
ailure (MLHF) questionnaire,
nd visual analog scales of global
ealth, dyspnea, and individual
orst symptom were completed at
aseline, and patients performed
he 6-min walk test if possible. At
, 2, 3, and 6 months, patients
epeated the time trade-off. At 3
onths, patients repeated all mea-
urements assessed at baseline.
The design of the ESCAPE trial pre-specified a new
econdary end point, the “preferred survival days,” the sum of
he days alive during 6 months after hospital discharge,
djusted by serial TTO scores (maximum 180 days). This was
alculated by weighting days alive in each interval (baseline to
, 1 to 2, 2 to 3, and 3 to 6 months) by the mean of the TTO
alues bracketing that interval, and summing across intervals
days between discharge and 1 month were weighted only by
he 1-month value). Thus, a day alive in an interval during
hich the patient preferred to trade 12 of 24 months for better
ealth would count as 0.5 day, compared with 1 day if the
atient was unwilling to trade any survival time. Days hospi-
alized or dead were designated with a value of 0.
tatistical methods. Baseline characteristics are summarized
or TTO groups as percent for categorical variables and median
or continuous variables. Continuous variables were compared
cross TTO groups using the Kruskal-Wallis tests. Categorical
ariables were compared across TTO groups using ordinal
ogistic regression with the TTO group as the response and the
ariable of interest as the predictor. (Patients with missing
aseline data are described in Table 1 and not included in
ther current analyses; patients without data at either 3 or 6
onths are not included in the analysis of changing pref-
rences.) The skewed distribution of responses (Fig. 1)
uggested grouping into 4 levels for baseline characteristics
nd for frequency of change between groups. (Division by
uartiles would have arbitrarily separated patients with the
ame discrete values.) This was a survivors’ analysis without
mputation for death or absence of serial studies. When
oth the 3- and 6-month results were available, the one with
argest absolute change from baseline was used.
Magnitude of change in functional scores was compared
mong groups defined by TTO change using Wilcoxon
ank sum tests. Direction of maximum change in TTO
reference (willing to change more, no change, willing to
rade less) was compared between randomized treatments
sing a Mantel-Haenszel chi-square test. The same test was
sed to determine the relationship between actual survival
nd the adjustments by patient preference for survival.
esults
TO distribution. The TTO values were available for 404
Abbreviations
and Acronyms
CAD  coronary artery
disease
HF  heart failure
MLHF  Minnesota Living
with Heart Failure
PAC  pulmonary artery
catheter
TTO  time trade-offatients at the time of randomization during hospitaliza-
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Changing Preferences for Survival With HF November 18, 2008:1702–8ion. The distribution was bimodal, with most values at the
xtremes (Fig. 1). Many patients (49%) expressed almost no
illingness to trade time at baseline (1 month of total
ossible 24 months). The next most common response
28%) was to trade almost all time to feel better for the
emaining time (scores closest to 0). The remainder of the
esponses were scattered, with small peaks at 6, 12, and 18
onths. Based on these results, patients were grouped into
Characterization of Patients With Missing TTO D
Table 1 Characterization of Patients With M
Baseline Factor
Patients Without
Baseline TTO Data
(n  29)
Male gender, % 79
Ethnic/racial minority, % 45
LVEF, % 20 (15, 25)
SBP, mm Hg 98 (90, 110)
BUN, mg/dl 37 (26, 54)
BNP, pg/ml 976 (477, 1,952)
6-min walk, m 37 (0, 162)
JVP, cm (%)
8 10
8–12 28
12–16 41
16 21
Edema, %
0–1 65
3–4 17
Freedom from worst symptom
(0–100; 100  best)
40 (20, 55)
Global score 35 (28, 52)
MLHF score 75 (66, 82)
Data are presented as median (25th, 75th percentiles) unless otherw
BNP  B-type natriuretic peptide; BUN  blood urea nitrogen; JVP 
Minnesota Living with Heart Failure questionnaire; SBP  systolic blo
Figure 1 Bimodal Distribution of Patient Preferences
Histogram showing distribution of time trade-off values at baseline. The x-axis is expre
no value to survival at the current state of health, and 0 months traded indicates full
months and then expressing as a fraction of 24. The values have been divided symmlevels: willing to trade almost all time (22 to 24 months)
nd willing to trade little or no time (0 time or up to 2 of 24
ossible months); then the remainder were divided at the
2-month value (12 to 21 months traded vs. 3 to 11 months
raded) (Table 2). The baseline demographics and resting
linical parameters did not distinguish between these 4
reference groups at the time of hospitalization, as trial
esign mandated presence of symptoms and signs of ele-
at Baseline or Follow-Up
g TTO Data at Baseline or Follow-Up
Patients With Baseline
TTO Who Survived
ithout Follow-Up TTO Data
(n  62)
Patients With Baseline
and TTO Data at
3 and/or 6 Months
(n  287)
68 75
47 39
19 (15, 20) 20 (15, 25)
101 (93, 113) 106 (95, 118)
26 (17, 41) 27 (19, 38)
585 (257, 1,042) 511 (193, 1,044)
8 (0, 162) 135 (6, 260)
12 8
40 41
17 31
12 20
64 68
11 11
30 (20, 50) 35 (20, 50)
40 (30, 50) 40 (30, 60)
73 (58, 84) 76 (65, 87)
cated.
r venous pressure; LVEF  left ventricular ejection fraction; MLHF 
sure; TTO  time trade-off.
n terms of months traded, such that 24 months indicates that the patient awards
These month-values can be changed into a utility from 0 to 1 by subtracting from 24
y into 4 ranges for group description and analysis of major changes.ata
issin
W
ise indissed i
value.
etricall
v
6
b
t
w
(
m
a
w
m
T
r
f
b
m
t
b
a
f
B
d
a
t
o
s
T
t
i
t
a
C
t
m
fi
o
o
s
1
e
d
o
w
b
s
a
d
t
e
r
o
p
p
s
t
(
t
c
P
e
s
T
t
s
(
o
a
p
i
t
m
m
3
v
m
p
C
D 6-min
1705JACC Vol. 52, No. 21, 2008 Stevenson et al.
November 18, 2008:1702–8 Changing Preferences for Survival With HFated filling pressures. For patients able to perform the
-min walk test, average distance was shorter than a city
lock for patients willing to trade at least one-half of their
ime (Table 2).
Baseline patient preference data was absent in 29 patients,
ho had symptoms similar to patients providing responses
Table 1). Repeat assessment of preferences at 3 or 6
onths was available for 287 patients, at 3 months for 270,
nd at 6 months for 210 patients. Of the 117 patients
ithout follow-up preference data, 55 had died during the 6
onths; the other 62 patients are characterized in Table 1.
here is no information on how often attempts were
epeated to obtain these missing data. Patients missing
ollow-up data were similar to patients with follow-up data,
ut blood pressure and 6-min walk distance were lower.
Of the 287 patients with values at baseline and at 3 to 6
onths, 193 had data at both 3 and 6 months, which yielded
he same result for 142 patients. When the values differed
etween 3 and 6 months, 24 patients were better at 3 months
nd 27 were better at 6 months; the greatest absolute change
rom baseline classified the overall change after hospitalization.
aseline and 3-month data were available without 6-month
ata for 77 patients, and baseline and 6-month data were
vailable without 3-month data for 17 patients.
The severity of symptoms was related to the amount of time
o be traded at baseline but the relationship became more
bvious at 3 months, when clinical status may have been more
table. The correlation between individual components and the
TO was strongest for the MLHF score at 3 months, but even
his correlation coefficient was only 0.33, indicating wide
ndividual variation. The specific item regarding depression in
he MLHF instrument was associated with the TTO value
t baseline and 3 months (both p  0.001).
hanges in TTO and functional status after hospitaliza-
ion. The average TTO score changed by only 4% (1/24
onths) on repeat assessment, with little change after the
rst post-discharge assessment (Fig. 2). Quantum change
ver time was measured as movement from one to another
f the 4 levels defined in Table 2. Of 287 patients in whom
haracteristics of Patients Grouped by Baseline TTO Levels
Table 2 Characteristics of Patients Grouped by Baseline TTO L
Characteristic
Willing to Trade
Almost All Time,
22–24 Months (n  112)
Willing to
One-Half or Mo
12–21 Months
Age, yrs 54 (45, 65) 58 (49, 63
Male gender, % 71 78
Minority, % 41 42
CAD, % 53 64
LVEF, % 20 (15, 25) 15 (15, 25
SBP, mm Hg 103 (96, 118) 102 (94, 11
BUN, mg/dl 27 (19, 40) 29 (20, 46
BNP, pg/ml 574 (276, 1,199) 575 (344, 1
6-min walk, m* 60 (0, 169) 169 (0, 198
ata are presented as median (25th, 75th percentiles) unless otherwise indicated. *Difference in
CAD  coronary artery disease; other abbreviations as in Table 1.erial measurements were made, the largest group was the o09 patients who initially had the maximum survival pref-
rence at baseline—thus, no range for increase—and did not
ecrease to a lower level (Fig. 3). The most common change
verall was an increased level of preference for survival,
hich occurred in 98 of 145 (68%) patients who began
elow the maximum level of survival preference. During
erial assessment, 25 patients remained willing to trade
lmost all time, and 9 had mid-level preference levels that
id not change (Fig. 3). Only 46 of 212 (23%) patients in
he range from which survival preference could worsen
xpressed a diminishing preference for survival.
Symptoms, 6-min walk distance, and MLHF scores
emained improved compared with baseline for the majority
f surviving patients. The MLHF scores remained im-
roved in 80% of patients at 6 months. For patients whose
references did change, those with improved preferences for
urvival were more likely to have substantial improvement in
heir worst symptom and in the MLHF questionnaire
Table 3). Changes in preference at 3 months after hospi-
alization were associated with changes in the depression
omponent of the MLHF questionnaire (p  0.0017).
atients with improved preference were more likely to have
xperienced an improvement in at least 2 functional mea-
urements (83% vs. 59%, p  0.01).
TO and trial end points. Change in the TTO assessment
hroughout the 6 months after discharge was a pre-specified
econdary end point in the ESCAPE trial. At each time point
1, 2, 3, and 6 months), there was greater increase in months
f preferred survival in the PAC arm than in the clinical arm,
s previously reported (7). Using the current analysis for the 4
reference levels defined post-hoc, there were similar levels of
mprovement (41% vs. 37%) and worsening (15% vs. 22%) in
he 2 groups at 3 months. When the greatest level of improve-
ent during the 6 months was analyzed, there was significantly
ore improvement (46% vs. 36%) and less worsening (22% vs.
2%) in the PAC arm (p  0.034). Slightly lower baseline
alues of survival preference in the PAC arm may have allowed
ore evidence of improvement. Approximately one-third of
atients in each strategy group had no change in preference
e,
45)
Willing to Trade
Less Than One-Half of Time,
3–11 Months (n  46)
Willing to Trade
Almost No Time,
0–2 Months (n  201)
59 (49, 72) 56 (46, 66)
80 73
30 41
42 53
20 (15, 25) 20 (15, 24)
100 (94, 118) 106 (93, 116)
32 (24, 51) 27 (17, 41)
681 (223, 1,107) 528 (159, 1,089)
198 (46, 299) 113 (0, 256)
walk across groups (p  0.003).evels
Trade
re Tim
(n 
)
)
5)
)
,395)
)ver time.
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Changing Preferences for Survival With HF November 18, 2008:1702–8The ESCAPE trial design pre-specified a novel second-
ry end point defined by adjusting the days alive out of the
ospital by the TTO value awarded by the patient to
urvival during each of the intervals after discharge. As
hown in Figure 4, this adjustment reduced the number of
alued days from the number of all days by an average of
4% with a wide standard deviation (32%), median reduc-
ion 5%. However, the devaluation of survival time was
ighest in the group with the shortest survival, indicating
hat those most likely to die were least likely to have cared
bout prolonging survival. Of 29 patients surviving 105
Figure 2 Changing Patient Preferences After Hospital Discharg
The proportions of patients in each time trade-off group at different times after ho
shown below the figure. Purple bars  willing to trade almost all (22 to 24 month
to trade less than one-half (3 to 11 months); green bars  willing to trade almost
of each interval. Definitions of intervals are as in Table 2. *Patients in each willing
that interval; cumulative deaths are shown as percent of 404 patients with baselin
Figure 3 Stability of Survival Preference
The pie graph shows the proportions of 287 patients with stable or changing
preferences in the 6 months after hospital discharge. Change was defined as
movement between the 4 preference levels described in Table 2. Patients
remaining in the highest survival preference are “stable high”; those remaining
in the lowest survival preference are “stable low.” Patients remaining in 1 of
the 2 other time-trade off groups are “stable mid-preference.” Although the
majority of patients demonstrated no change in preference, more patients
described an increase than a decrease in preference for survival.bays, 9 (31%) indicated that they would trade90% of their
urvival days to feel well for the time remaining, compared
ith 6% of patients surviving all 180 days (p  0.0015).
iscussion
his study provides new insight into how often patient
references change toward survival versus quality of life.
illingness to trade remained largely bimodal, with more
atients unwilling to trade any time than willing to trade
lmost all remaining time in order to enjoy better health.
ost patient preferences were stable after hospitalization,
ut increases from one level to another were twice as
ommon as decreases. Most patients had sustained symp-
omatic improvement, which was somewhat greater in
atients with an increased survival preference. Therapy
uided by the PAC in the hospital was associated with a
lightly greater increase in preference for survival. Adjust-
ent of days alive for patient preference decreased total days
y a small amount, which was most substantial when
urvival time was short.
hanging patient preferences and symptoms. The TTO
nstrument, studied in other chronic diseases (6,8,9), inte-
rates multiple factors that determine patient priorities
5,10). In previous studies, the TTO has been assessed
uring intensive care (4) or stable outpatient care (5).
rospective serial assessment in the ESCAPE trial helps
ap the trajectory of patient preferences from decompen-
ation in hospital through the transition to the chronic
utpatient setting. Patient preferences were relatively stable
ver time, particularly when survival preference was high at
discharge are shown. The number of patients responding for each interval is
bars  willing to trade one-half or more (12 to 21 months); blue bars  willing
(0 to 2 months); black bars  cumulative number of patients dying by the end
o-trade category at each interval are shown as percent of patients with data at
a.e
spital
s); red
none
ness-t
e dataseline (Fig. 3). The largest group of patients (38%) was
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November 18, 2008:1702–8 Changing Preferences for Survival With HFnwilling to trade substantial time at baseline and remained
nwilling to trade, always preferring to live as long as
ossible. Change was more likely among patients who
laced less value on survival during their decompensation, in
hom preference for survival was twice as likely to increase
s decrease after hospital discharge. Improvements in pref-
rences seen by 1 month were generally sustained during the
emainder of the trial. This improvement may reflect
ecovery after a transient dip in survival preference at
ospitalization, or improvement to a survival preference
bove that before hospitalization.
The TTO correlated directionally, although modestly
nd nonlinearly, with symptoms and function, and also
orrelated with depression. As for angina (10), many pa-
ients with severe symptoms remained unwilling to trade
ime, whereas others with moderate symptoms would trade
onsiderable time. Individual factors such as family dynam-
Figure 4 Patient-Preferred Survival
Days alive adjusted by time trade-off. For each patient, the x-y plot compares the a
erence described by the patient during each interval (see Methods). Overall, the m
highest proportion of days devalued by low preference for survival (p  0.0015), w
feel better, compared with 6% of patients surviving all 180 days.
mprovement in Functional Parameters by 3 Months in Relation to
Table 3 Improvement in Functional Parameters by 3 Months in
Functional Parameter of Improvement*
Increased Survival
Preference
at 3 Months
(n  86)
Patient global health VAS 19 (28)
Breathing VAS 12 (31)
Freedom from worst symptom VAS 25 (31)
MLHF score 22 (23)
6-min walk, m 130 (123)
Improvement in at least 2 of the above† 83%
ata are presented as mean (SD), except for the last row. All p values from Wilcoxon rank su
easurements except MLHF (Minnesota Living with Heart Failure) questionnaire, in which lower sc
t least 5 for MLHF, and increase of at least 15 m (50 ft) for 6-min walk distance.cs, religious beliefs, and financial burden may play a strong
ole in preferences. Thus, HF symptoms are only 1 dimen-
ion of patient preference for survival, but together with
atient education and coping skills, they are probably the
ost amenable to medical intervention. Symptoms im-
roved in most patients, with greater improvement in
atients who had increased preferences for survival after
ischarge. Symptoms and functional capacity may contrib-
te more to the changes in preferences than to the absolute
references, for which the nonmedical determinants may
ot often change during brief follow-up. Preference for
urvival over perceived quality of life cannot be inferred
rom the quality scores alone.
mpact of therapy during hospitalization. The TTO
uestionnaire indicated slightly but significantly more im-
rovement in preference for survival among patients whose
ospital therapy had been guided by the PAC. Dyspnea and
survival days during 6 months to the survival days adjusted for the survival pref-
of patients had 10% devalued days. Patients dying before 105 days had the
% of patients indicating that they would trade 90% of their remaining days to
ging Preferences
tion to Changing Preferences
creased Survival
Preference
at 3 Months
(n  50)
Total Number With Changing
Preferences and Repeated
Parameter Measurement
(n  136) p Value
8 (27) 95 0.126
9 (22) 49 0.56
8 (23) 92 0.0065
10 (25) 94 0.014
100 (166) 59 0.27
59% 96 0.011
except the last value, which is from likelihood ratio chi-square test. *Indicated by “” for all
flect less limitation. †Defined as increase of at least 10 for visual analog score (VAS), decrease ofctual
ajority
ith 31Chan
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Changing Preferences for Survival With HF November 18, 2008:1702–8ugular venous distention correlate with willingness to trade
ime to feel better (5). Patients in both arms of the ESCAPE
rial had similar degrees of relief in the hospital, although there
as slightly more diuresis, better renal function, and more
eduction of mitral regurgitation during reduction of filling
ressures measured by the PAC (11). The improvement in the
LHF score was significantly greater at 1 month for patients
fter PAC-guided therapy (7). The invasive nature of PAC
ay have conferred a stronger sense of therapeutic efficacy,
reating an expectation of greater improvement. It is also
ossible that the apparent impact of PAC on patient prefer-
nce was a chance finding.
reference-adjusted survival. Survival adjusted for patient
reference was pre-specified during the design of the ES-
APE trial. Previous trials reporting quality-adjusted life-
ears for HF populations have generally imputed utilities
ased on symptom scores (12,13). Adjusting the actual days
live out of hospital by the utility function of how the
atients valued their days integrates survival and quality
rom the patients’ standpoint, without introducing assump-
ions based on our own attitudes. Adjustment for patient
alue diminished the counted number of days by 10% for
ost patients (Fig. 4). However, the diminution was most
rofound for patients who survived 3 months, 31% of
hom stated willingness to trade 90% of their remaining
ays to feel better. It is a vital paradox that the patients most
ikely to contribute mortality end points may be those to
hom the length of survival seems least important.
tudy limitations. This trial is limited by missing data for
TO preferences and symptoms, which have plagued other
rials of advanced HF in which such measures are not
rimary end points (14). Analysis of patients for whom
reference data are missing revealed few differences in
aseline characteristics, with the exception of patients miss-
ng because of death, for which quality is undeterminable.
eath was excluded rather than assigned a worst rank,
ecause the study addressed quality of life for survivors, who
ace therapeutic choices. This and other trials highlight the
mperative to increase attention to quality-of-life data com-
letion during monitoring.
The TTO and other utility tools are limited by the hypo-
hetical nature of the questions. Facing imminent mortality,
atients may prefer survival over comfort. However, the TTO
as been used extensively in oncology (8,9), and it correlates
ell with the standard gamble (5,15). Although it is clear that
references should be reviewed often, the optimal mode of
ssessment has not been established.
onclusions
entering care with the patient. This study highlights the
omplexity of patient-centered care for chronic HF. Because
references often differ between patients with similar symp-
oms, our assumptions based on symptom burden may not
dequately guide therapy. Most patients prefer survival even
uring decompensation, and patients who would trade
K
hurvival time are those most likely to change their prefer-
nce. These findings suggest a framework of care in which
urvival preferences would be best assessed after hospital
ischarge. Further study is necessary to understand how
lucidation of patient preferences should guide decisions
egarding medical and device therapy, resuscitation, and
ew therapies for advanced disease.
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